FDA Approves First Oral GLP-1 Weight Loss Pill from Novo Nordisk

TL;DR Summary
The FDA has approved the first oral GLP-1 pill for obesity from Novo Nordisk, expected to launch in early 2026, offering a new treatment option that could expand access and compete with Eli Lilly in the booming weight loss drug market.
- FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk CNBC
- Novo Nordisk wins US approval for weight-loss pill Reuters
- With FDA approval of Wegovy pill, new era of oral GLP-1 weight loss drugs begins CNN
- Novo Nordisk Gets US Approval for Wegovy Obesity Pill Bloomberg.com
- GLP-1 pills are on the way. Here's what to know : Short Wave NPR
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
91%
473 → 41 words
Want the full story? Read the original article
Read on CNBC